Nilesh Kumar

Mr. Kumar is a Partner at Novo Ventures and is based in Boston. In addition to Milestone, he also serves on Boards of Tarveda, Cirius Therapeutics, Morphic Therapeutics, Rgenix, Anokion, and KanyosBio.

Prior to Novo, Nilesh was Senior Investment Director at Merck and led investments in f-Star, RaNA (TranslateBio), Padlock, Auxogyn (Progyny). In addition to his venture role, Nilesh led several strategic licensing transactions for Merck Serono in the field of oncology and autoimmune diseases. Nilesh received his PhD and MBA from Harvard University, and an undergraduate degree from the University of Cambridge, UK.